Kaneka (4118) Q2 2025 earnings summary

Executive summary

• Net sales rose 7.0% year-over-year to ¥395,963 million for 1H FY2024, with operating income up 51.5% to ¥19,101 million and net income attributable to owners up 14.2% to ¥10,162 million.

• All major business segments except Health Care Solutions Unit posted higher sales and profits; Health Care saw flat sales and a temporary profit decline due to shipment timing in Pharma.

• Strong growth in Material, Quality of Life, and Nutrition Solutions Units, with continued momentum expected in 2H.

• The company maintained strong momentum despite global economic stagnation and geopolitical uncertainties.

Financial highlights

• Operating income margin improved from 3.4% to 4.8% year-over-year.

• Net income per share increased from ¥137.09 to ¥160.48.

• Equity ratio rose to 53.0% as of September 30, 2024.

• Free cash flow was negative at ¥(7.4) billion for 1H FY2024, with cash and cash equivalents at ¥38,073 million at period end.

• Comprehensive income declined to ¥9,477 million from ¥26,201 million year-over-year, mainly due to negative valuation differences on securities.

Outlook and guidance

• Full-year FY2024 forecast maintained: net sales ¥790,000 million (+3.6%), operating income ¥38,000 million (+16.6%), net income attributable to owners ¥24,500 million (+16.3%), EPS ¥388.18.

• Growth momentum expected to strengthen in 2H, especially in Material and Quality of Life segments.

• Pharma segment to see concentrated shipments and profit recovery in 4Q.